US Patent 11084845 C-3 and C-17 modified triterpenoids as HIV-1 inhibitors
Patent 11084845 was granted and assigned to ViiV Healthcare on August, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+300 characters)
Article
Patent abstract
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+11 properties)
Infobox
Patent Inventor Names
Alicia Regueiro-Ren0
Beata Nowicka-Sans0
Brian Lee Venables0
Ira B. Dicker0
Jacob Swidorski0
Jie Chen0
Nicholas A. Meanwell0
Ny Sin0
Richard A. Hartz0
Sing-Yuen Sit0
Yan Chen0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110848450
Date of Patent
August 10, 2021
0Patent Application Number
201908070
Date Filed
August 7, 2019
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11084845 C-3 and C-17 modified triterpenoids as HIV-1 inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11084845
Date of patent
August 10, 2021
Patent application number
20190807
Date Filed
August 7, 2019
Find more entities like US Patent 11084845 C-3 and C-17 modified triterpenoids as HIV-1 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.